These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 22889281)

  • 1. Solubility-driven optimization of phosphodiesterase-4 inhibitors leading to a clinical candidate.
    Press NJ; Taylor RJ; Fullerton JD; Tranter P; McCarthy C; Keller TH; Arnold N; Beer D; Brown L; Cheung R; Christie J; Denholm A; Haberthuer S; Hatto JD; Keenan M; Mercer MK; Oakman H; Sahri H; Tuffnell AR; Tweed M; Tyler JW; Wagner T; Fozard JR; Trifilieff A
    J Med Chem; 2012 Sep; 55(17):7472-9. PubMed ID: 22889281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors.
    Kümmerle AE; Schmitt M; Cardozo SV; Lugnier C; Villa P; Lopes AB; Romeiro NC; Justiniano H; Martins MA; Fraga CA; Bourguignon JJ; Barreiro EJ
    J Med Chem; 2012 Sep; 55(17):7525-45. PubMed ID: 22891752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology, clinical efficacy, and tolerability of phosphodiesterase-4 inhibitors: impact of human pharmacokinetics.
    Tenor H; Hatzelmann A; Beume R; Lahu G; Zech K; Bethke TD
    Handb Exp Pharmacol; 2011; (204):85-119. PubMed ID: 21695636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and Optimization of 4-(8-(3-Fluorophenyl)-1,7-naphthyridin-6-yl)transcyclohexanecarboxylic Acid, an Improved PDE4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease (COPD).
    Press NJ; Taylor RJ; Fullerton JD; Tranter P; McCarthy C; Keller TH; Arnold N; Beer D; Brown L; Cheung R; Christie J; Denholm A; Haberthuer S; Hatto JD; Keenan M; Mercer MK; Oakman H; Sahri H; Tuffnell AR; Tweed M; Trifilieff A
    J Med Chem; 2015 Sep; 58(17):6747-52. PubMed ID: 26288344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of asthma and COPD.
    Shan WJ; Huang L; Zhou Q; Jiang HL; Luo ZH; Lai KF; Li XS
    Bioorg Med Chem Lett; 2012 Feb; 22(4):1523-6. PubMed ID: 22297114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological activity of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel and potent phosphodiesterase type 4 inhibitors.
    Taltavull J; Serrat J; Gràcia J; Gavaldà A; Córdoba M; Calama E; Montero JL; Andrés M; Miralpeix M; Vilella D; Hernández B; Beleta J; Ryder H; Pagès L
    Eur J Med Chem; 2011 Oct; 46(10):4946-56. PubMed ID: 21871695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of triazines as potent, selective and orally active PDE4 inhibitors.
    Gewald R; Grunwald C; Egerland U
    Bioorg Med Chem Lett; 2013 Aug; 23(15):4308-14. PubMed ID: 23806553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of 2,3-disubstituted pyridines as potent, non-emetic PDE4 inhibitors.
    Kawasaki M; Fusano A; Nigo T; Nakamura S; Ito MN; Teranishi Y; Matsumoto S; Toda H; Nomura N; Sumiyoshi T
    Bioorg Med Chem Lett; 2014 Jun; 24(12):2689-92. PubMed ID: 24794103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-Aided Identification and Optimization of Tetrahydro-isoquinolines as Novel PDE4 Inhibitors Leading to Discovery of an Effective Antipsoriasis Agent.
    Zhang X; Dong G; Li H; Chen W; Li J; Feng C; Gu Z; Zhu F; Zhang R; Li M; Tang W; Liu H; Xu Y
    J Med Chem; 2019 Jun; 62(11):5579-5593. PubMed ID: 31099559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of potent selective bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model. Part II: optimization studies and demonstration of in vivo efficacy.
    Plummer MS; Cornicelli J; Roark H; Skalitzky DJ; Stankovic CJ; Bove S; Pandit J; Goodman A; Hicks J; Shahripour A; Beidler D; Lu XK; Sanchez B; Whitehead C; Sarver R; Braden T; Gowan R; Shen XQ; Welch K; Ogden A; Sadagopan N; Baum H; Miller H; Banotai C; Spessard C; Lightle S
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3443-7. PubMed ID: 23597790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of 2,3-disubstituted pyridines as potent, orally active PDE4 inhibitors.
    Kato Y; Kawasaki M; Nigo T; Nakamura S; Fusano A; Teranishi Y; Ito MN; Sumiyoshi T
    Bioorg Med Chem; 2013 Sep; 21(18):5851-4. PubMed ID: 23910988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the new benzimidazole derivative TAS-203, an orally active phosphodiesterase 4 inhibitor, on airway inflammation in rats and emetic responses in ferrets.
    Asaka N; Kakuo H; Ohmori K; Sasaki E; Togawa M; Yamada S; Oka T; Kiniwa M
    Arzneimittelforschung; 2010; 60(9):564-70. PubMed ID: 21117500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphodiesterase inhibitors. Part 2: design, synthesis, and structure-activity relationships of dual PDE3/4-inhibitory pyrazolo[1,5-a]pyridines with anti-inflammatory and bronchodilatory activity.
    Ochiai K; Ando N; Iwase K; Kishi T; Fukuchi K; Ohinata A; Zushi H; Yasue T; Adams DR; Kohno Y
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5451-6. PubMed ID: 21764304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of 3,5-disubstituted-1,2,4-oxadiazoles as potent inhibitors of phosphodiesterase4b2.
    Kumar D; Patel G; Vijayakrishnan L; Dastidar SG; Ray A
    Chem Biol Drug Des; 2012 May; 79(5):810-8. PubMed ID: 22176507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of 2,4-disubstituted oxazole derivatives as potential PDE4 inhibitors.
    Li YS; Hu DK; Zhao DS; Liu XY; Jin HW; Song GP; Cui ZN; Zhang LH
    Bioorg Med Chem; 2017 Mar; 25(6):1852-1859. PubMed ID: 28196708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology of a novel, orally active PDE4 inhibitor.
    Dastidar SG; Ray A; Shirumalla R; Rajagopal D; Chaudhary S; Nanda K; Sharma P; Seth MK; Balachandran S; Gupta N; Palle V
    Pharmacology; 2009; 83(5):275-86. PubMed ID: 19321962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of oral and inhaled PDE4 inhibitors.
    Ting PC; Lee JF; Kuang R; Cao J; Gu D; Huang Y; Liu Z; Aslanian RG; Feng KI; Prelusky D; Lamca J; House A; Phillips JE; Wang P; Wu P; Lundell D; Chapman RW; Celly CS
    Bioorg Med Chem Lett; 2013 Oct; 23(20):5528-32. PubMed ID: 24018187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Montmorillonite K-10 mediated green synthesis of cyano pyridines: Their evaluation as potential inhibitors of PDE4.
    Ram Reddy T; Rajeshwar Reddy G; Srinivasula Reddy L; Jammula S; Lingappa Y; Kapavarapu R; Meda CL; Parsa KV; Pal M
    Eur J Med Chem; 2012 Feb; 48():265-74. PubMed ID: 22217868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-neutrophilic inflammatory activity of ASP3258, a novel phosphodiesterase type 4 inhibitor.
    Kubo S; Kobayashi M; Iwata M; Miyata K; Takahashi K; Shimizu Y
    Int Immunopharmacol; 2012 Jan; 12(1):59-63. PubMed ID: 22041526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-asthmatic effect of ASP3258, a novel phosphodiesterase 4 inhibitor.
    Kobayashi M; Kubo S; Hirano Y; Kobayashi S; Takahashi K; Shimizu Y
    Int Immunopharmacol; 2012 Jan; 12(1):50-8. PubMed ID: 22036845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.